SARS-CoV-2 Infection Is Associated with Uncontrolled HIV Viral Load in Non-Hospitalized HIV-Infected Patients from Gugulethu, South Africa.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
03 06 2022
Historique:
received: 13 04 2022
revised: 26 05 2022
accepted: 30 05 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 28 6 2022
Statut: epublish

Résumé

In South Africa, high exposure to SARS-CoV-2 occurs primarily in densely populated, low-income communities, which are additionally burdened by highly prevalent Human Immunodeficiency Virus (HIV). With the aim to assess SARS-CoV-2 seroprevalence and its association with HIV-related clinical parameters in non-hospitalized patients likely to be highly exposed to SARS-CoV-2, this observational cross-sectional study was conducted at the Gugulethu Community Health Centre Antiretroviral clinic between October 2020 and June 2021, after the first COVID-19 wave in South Africa and during the second and beginning of the third wave. A total of 150 adult (median age 39 years [range 20−65 years]) HIV-infected patients (69% female; 31% male) were recruited. 95.3% of the cohort was on antiretroviral therapy (ART), had a median CD4 count of 220 cells/µL (range 17−604 cells/µL) and a median HIV viral load (VL) of 49 copies/mL (range 1−1,050,867 copies/mL). Furthermore, 106 patients (70.7%) were SARS-CoV-2 seropositive, and 0% were vaccinated. When stratified for HIV VL, patients with uncontrolled HIV viremia (HIV VL > 1000 copies/mL) had significantly higher odds of SARS-CoV-2 seropositivity than patients with HIV VL < 1000 copies/mL, after adjusting for age, sex and ART status (p = 0.035, adjusted OR 2.961 [95% CI: 1.078−8.133]). Although the cause−effect relationship could not be determined due to the cross-sectional study design, these results point towards a higher risk of SARS-CoV-2 susceptibility among viremic HIV patients, or impaired HIV viral control due to previous co-infection with SARS-CoV-2.

Identifiants

pubmed: 35746693
pii: v14061222
doi: 10.3390/v14061222
pmc: PMC9229655
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Adv Immunol. 2013;119:51-83
pubmed: 23886064
Clin Microbiol Infect. 2021 Nov;27(11):1678-1684
pubmed: 34186209
EClinicalMedicine. 2022 Jan 26;44:101283
pubmed: 35128369
AIDS Res Ther. 2021 Jan 6;18(1):1
pubmed: 33407664
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Lancet HIV. 2020 Aug;7(8):e554-e564
pubmed: 32473657
Lancet HIV. 2020 Jun;7(6):e383
pubmed: 32416771
Lancet HIV. 2021 Sep;8(9):e554-e567
pubmed: 34363789
Clin Infect Dis. 2021 Nov 2;73(9):e2845-e2846
pubmed: 33211091
Clin Infect Dis. 2021 Oct 5;73(7):e2005-e2015
pubmed: 32860699
Epidemiology. 2020 Nov;31(6):e49-e51
pubmed: 32773469
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
PLoS One. 2022 Mar 24;17(3):e0265488
pubmed: 35324923
Trop Med Int Health. 2016 Sep;21(9):1124-30
pubmed: 27371814
Front Plant Sci. 2021 Mar 31;12:589940
pubmed: 33868324
Nat Microbiol. 2020 Dec;5(12):1598-1607
pubmed: 33106674
Clin Infect Dis. 2020 Nov 19;71(16):2294-2297
pubmed: 32472138
BMJ Glob Health. 2020 Aug;5(8):
pubmed: 32816953
Clin Infect Dis. 2020 Dec 31;71(11):2933-2938
pubmed: 32594164
Glob Health Sci Pract. 2021 Sep 30;9(3):433-443
pubmed: 34593571
Clin Infect Dis. 2020 Nov 19;71(16):2276-2278
pubmed: 32407467
Infection. 2020 Oct;48(5):681-686
pubmed: 32394344
AIDS. 2022 Feb 1;36(2):161-168
pubmed: 34934017
Nature. 2021 Dec;600(7887):33-36
pubmed: 34853449
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Lancet Infect Dis. 2022 Jun;22(6):821-834
pubmed: 35298900
Ann Med Psychol (Paris). 2020 Sep;178(7):695-698
pubmed: 32836300
Gates Open Res. 2021 Jun 4;5:90
pubmed: 34286217
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
BMC Infect Dis. 2017 Jan 26;17(1):98
pubmed: 28122494
PLoS One. 2021 Feb 25;16(2):e0247852
pubmed: 33630977
J Med Virol. 2021 Mar;93(3):1478-1488
pubmed: 32813298
Clin Infect Dis. 2021 Oct 5;73(7):e2095-e2106
pubmed: 33095853
Elife. 2021 Oct 05;10:
pubmed: 34608862
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089
Clin Infect Dis. 2022 Feb 02;:
pubmed: 35134129
Front Med (Lausanne). 2021 Jun 14;8:666949
pubmed: 34195209
Clin Infect Dis. 2021 Sep 02;:
pubmed: 34472583
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451

Auteurs

Humaira Lambarey (H)

International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town 7925, South Africa.
Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa.
Department of Integrative Biomedical Sciences, Division of Medical Biochemistry, University of Cape Town, Cape Town 7925, South Africa.

Melissa J Blumenthal (MJ)

International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town 7925, South Africa.
Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa.
Department of Integrative Biomedical Sciences, Division of Medical Biochemistry, University of Cape Town, Cape Town 7925, South Africa.

Abeen Chetram (A)

International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town 7925, South Africa.

Wendy Joyimbana (W)

Desmond Tutu Health Foundation, Cape Town 7925, South Africa.

Lauren Jennings (L)

Desmond Tutu Health Foundation, Cape Town 7925, South Africa.

Marius B Tincho (MB)

Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa.
Department of Pathology, Division of Medical Virology, University of Cape Town, Cape Town 7925, South Africa.

Wendy A Burgers (WA)

Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa.
Department of Pathology, Division of Medical Virology, University of Cape Town, Cape Town 7925, South Africa.
Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town 7925, South Africa.

Catherine Orrell (C)

Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa.
Desmond Tutu Health Foundation, Cape Town 7925, South Africa.

Georgia Schäfer (G)

International Centre for Genetic Engineering and Biotechnology (ICGEB), Cape Town 7925, South Africa.
Faculty of Health Sciences, Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, Cape Town 7925, South Africa.
Department of Integrative Biomedical Sciences, Division of Medical Biochemistry, University of Cape Town, Cape Town 7925, South Africa.
Wellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town 7925, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH